Table 2.
T cell activation/exhaustion, and NK and myeloid cells activation and function in HCV and HCV/HCV subjects before and after multiple testing adjustment
| Category | Variable Name | HCV Median (25th, 75th quartile) |
N (HCV) |
HIV/HCV Median (25th, 75th quartile) |
N (HIV/HCV) |
P (HCV vs HIV/HCV) |
P (BY*: HCV vs HIV/HCV) |
|---|---|---|---|---|---|---|---|
| T cells | CD3+CD4+ % | 40.2 (36.1, 47.2) | 33 | 18.7 (13.7, 25.3) | 44 | <0.001 | <0.001 |
| CD3+CD8+ % | 24 (19.5, 27.5) | 33 | 45 (38.9, 51.6) | 44 | <0.001 | <0.001 | |
| T cell activation | CD3+CD8+CD38+ % | 7 (5.9, 9.4) | 33 | 24.8 (14.9, 30) | 44 | <0.001 | <0.001 |
| CD3+CD8+HLADR+ % | 0 (0, 0.1) | 33 | 0.1 (0.1, 0.3) | 44 | <0.001 | 0.01 | |
| CD3+CD8−CD38+ % | 15.9 (10.5, 17.7) | 33 | 11 (7.2, 14.7) | 44 | 0.03 | nsᵼ | |
| CD3+CD8+CD38+ % of CD3+CD8+ | 34.6 (27.1, 43.7) | 33 | 55.8 (38.1, 68.5) | 44 | <0.001 | <0.001 | |
| CD3+CD8−CD38+ % of CD3+CD8− | 36.6 (28.4, 40.6) | 33 | 54.6 (45.8, 63) | 44 | <0.001 | <0.001 | |
| CD3+CD8−HLA-DR+ % of CD3+CD8− | 0.3 (0.2, 0.5) | 33 | 0.8 (0.4, 1.1) | 44 | 0.02 | ns | |
| MFI of CD38 on CD3+CD8+ | 156 (118, 201) | 33 | 299.5 (178, 444) | 44 | <0.001 | <0.001 | |
| MFI of HLA-DR on CD3+CD8+ | 46.8 (41.9, 51.4) | 33 | 50.4 (42.3, 62.3) | 44 | 0.04 | ns | |
| MFI of CD38 on CD3+CD8− | 166 (131, 206) | 33 | 338 (259, 418) | 44 | <0.001 | <0.001 | |
| MFI of HLA-DR on CD3+CD8− | 44.6 (40.3, 51.2) | 33 | 52.6 (45.9, 64.1) | 44 | 0.009 | ns | |
| Tregs | CD4+FoxP3+CD25+ % | 0.8 (0.6, 0.9) | 33 | 0.4 (0.3, 0.7) | 44 | <0.001 | 0.02 |
| T cell exhaustion | CD3+CD8+BTLA+CD160+ % of CD3+CD8+ | 0.5 (0.1, 1.2) | 33 | 1.5 (0.5, 3.6) | 44 | 0.01 | ns |
| MFI of CD160 on CD3+CD8− | 24.4 (20.2, 26.9) | 33 | 29.1 (22.3, 33.8) | 44 | 0.01 | ns | |
| MFI of CD160 on CD3+CD8+ | 35 (27.9, 46.6) | 33 | 52.7 (44.5, 71) | 44 | <0.001 | 0.007 | |
| MFI of CTLA-4 on CD3+CD8+ | 63.4 (44.1, 72.5) | 33 | 69.3 (59.8, 91.1) | 44 | 0.02 | ns | |
| Myeloid cells activation/apoptosis | MFI of CD86 on CD3−CD14+ | 325 (287,364) | 33 | 333.5 (306.8, 389) | 44 | 0.03 | ns |
| MFI of CD86 on CD19−BDCA1+CD11c+ | 279 (261, 296) | 33 | 296.5 (267, 321.5) | 44 | 0.004 | ns | |
| MFI of TRAIL on CD3−CD14+ | 53.1 (28.8, 69) | 33 | 61.4 (50.2,80.4) | 44 | 0.004 | ns |
| Category | Variable Name | HCV Median (25th, 75th quartile) |
N (HCV) |
HIV/HCV Median (25th, 75th quartile) |
N (HIV/HCV) |
P (HCV vs HIV/HCV) |
P (* BY: HCV vs HIV/HCV) |
|---|---|---|---|---|---|---|---|
| Myeloid cells activation/apoptosis | MFI of TRAIL on BDCA2+BDCA4+ | 75.5 (66.7,86.3) | 33 | 86.5 (77,94.7) | 44 | 0.02 | ns |
| NK cell activation | MFI of CD69 on ǂ Lin3−CD56dimCD16+ | 70.2 (59.8, 73.7) | 32 | 72.8 (65, 83.8) | 43 | 0.04 | ns |
| MFI of CD69 on Lin3−CD56bright | 75.2 (70, 80) | 32 | 82.4 (72.2, 90.7) | 43 | 0.04 | ns | |
| IFN-αR on NK cells | MFI of IFN-αR on Lin3−CD56dimCD16+ | 526 (456, 627.5) | 32 | 480 (367, 520.5) | 43 | 0.01 | ns |
| MFI of IFN-αR on Lin3−CD56dimCD16− | 465.5 (427, 560.2) | 32 | 410 (353, 475.5) | 43 | 0.02 | ns | |
| Signaling (Constitutive STAT-1) | MFI of p-STAT-1 on Lin3−CD56+CD16+ | 57.7 (47.2, 66) | 33 | 68 (59.3, 78.7) | 43 | <0.001 | 0.05 |
| MFI of p-STAT-1 on Lin3−CD56+CD16− | 101 (76.1, 110) | 33 | 116 (93.6, 136.5) | 43 | 0.006 | ns | |
| MFI of p-STAT-1 on Lin3−CD56−CD16+ | 57.4 (45.1, 70.2) | 33 | 68.8 (60.1, 88.5) | 43 | 0.002 | ns | |
| MFI of p-STAT-1 on CD3−CD14+ | 145 (129, 157) | 33 | 171 (145.5, 194) | 43 | <0.001 | 0.02 | |
| MFI of p-STAT-1 on BDCA2+BDCA4+ | 116 (83.9, 135) | 33 | 134 (113, 151) | 43 | 0.01 | ns | |
| NK cell direct cytotoxicity | AUC§ Constitutive | 1080.3 (631.9, 1716.2) | 29 | 889.9 (401.2, 1188.2) | 40 | 0.04 | N/A¶ |
| AUC IFNα-induced - AUC constitutive | 320.1 (173.4, 419) | 29 | 157.5 (73.7, 277.6) | 40 | 0.02 | N/A |
*
BY: Benjamini and Yekutieli adjusted p.
ᵼ
ns: non-significant.
ǂ
Lin3: CD3, CD14, CD19, CD20.
§
AUC: Area under the curve.
¶
N/A: not applicable.